| Congresso Brasileiro de Microbiologia 2023 | Resumo: 1085-2 | ||||
Resumo:Each year approximately 1.5 million people die from yeast infections, and 80% of causes of death from fungal sepsis are caused by Candida sp. Although the incidence of deaths from Candida auris has been increasing since 2019, the main cause of candidiasis in the world is Candida albicans. Other species such as C. tropicalis, C. parapsilosis, C. krusei and C. glabrata also play an important role in causing systemic candidiasis in patients with compromised immune function. Cutaneous candidiasis is a disease caused by Candida sp. localized at the skin that appears as thick red patches and plaques with satellite lesions in the form of papules and pustules around them. These yeasts mainly affect the intertriginous areas, as the axillae, under the breasts, and groin. These fungal infections are a major public health problem and frequently affect patients in intensive care units in hospitals. The imidazolium salts (IS) have differentiated physicochemical properties and chemical structures that allow structural modifications both in the cation and in the anion, which provide different biological activities already proven, such as antimicrobial, antitumor, among others. In this context, the aim of this study is to evaluate the effectiveness of the IS 1-hexadecyl-3-methylimidazolium chloride (C16MImCl) and 1-methyl-3-octadecylimidazolium chloride (C18MImCl) against different Candida sp. comparing the activity of these compounds with miconazole, an antifungal widely used in clinical medicine, to develop an effective antifungal formulation. The IS used were synthesized following literature procedures. The minimum inhibitory concentration (MIC) assay was performed according to international standard protocols CLSI M27-A2 and CLSI M38-A. The MIC of the two IS (C16MImCl and C18MImCl) were determined using the serial broth dilution method. The assays were performed in duplicate and the results were verified after 24 and 48 h. Ten yeast strains (four strains from systemic candidiasis (C. tropicalis ATCC13803, C. Krusei ATCC34135, C. glabrata ATCC2001, C. albicans ATCC44858) and six strains from cutaneous candidiasis (C. albicans CFP00107, C. tropicalis CPF00319, C. parapsilosis CFP00893, C. albicans CFP00895, C. albicans CPF00283, C. albicans CFP00292) that are part of the mycology collection of the Multidisciplinary Group in Medical and Microbiological Chemistry were selected. For all ten yeast isolates tested, the MIC for the IS C16MImCl and C18MImCl were 1 μg/mL and ranged between 1 μg/mL and 2 μg/mL, respectively. MIC were obtained with miconazole for C. tropicalis ATCC13803, C. albicans ATCC44858, C. albicans CFP00107, C. tropicalis CPF00319, C. parapsilosis CFP00893, C. albicans CPF00283 and C. albicans CFP00292 of 4 μg/mL, for C. Krusei ATCC34135 of 32 μg/mL, for C. glabrata ATCC2001 of 8 μg/mL and for C. albicans CFP00895 of 2 μg/mL. As such, the IS C16MImCl and C18MImCl proved to be potent growth inhibitors of Candida sp. with better MIC values compared to the commercial antifungal miconazole. This study suggests the potential use of IS as an alternative to commercial fungicides for the treatment of systemic and cutaneous candidiasis. Palavras-chave: Imidazolium ionic liquid, Antifungal, Antimicrobial, Minimum inhibitory concentration, Miconazole Agência de fomento:CNPq, MCTIC, FUNDEP, SEBRAE, CAPES | |||||